Target pathway validation for Compound Kushen Injection active against cancer cells

Area of Science:

• Pharmacology
• Genetics
• Traditional Chinese Medicine

Background:

• Traditional Chinese medicines feature complex natural product mixtures with multi-target actions, posing challenges for target discovery.
• Previous transcriptomic studies identified candidate target genes for Compound Kushen Injection (CKI).

Purpose of the Study:

• To demonstrate the involvement of multiple genetic targets in the diverse pharmacological activities of Compound Kushen Injection.
• To validate candidate genes identified through transcriptomic analysis for CKI's mechanism of action.

Main Methods:

• Utilized CRISPR/CAS gene editing technology to knock out eight key genes across four candidate pathways in four cell lines.
• Assessed the impact of gene knockouts on cellular activities and CKI's pharmacological efficacy.

Main Results:

• Gene knockouts generally reduced cellular activities, with varying sensitivity across cell lines.
• Knocking out MYD88 and NFkB genes enhanced CKI efficacy, while CDKN1A had minimal impact.
• IL24, CYP1B1, and CYP1A1 were identified as crucial for CKI's inhibition of tumor cell migration and cell cycle arrest.

Conclusions:

• Findings validate previous transcriptomic analyses of CKI.
• The study underscores the complexity of multi-target synergistic actions in natural product mixtures.
• Confirms the intricate pharmacological mechanisms underlying Traditional Chinese Medicine efficacy.